Cancer Drugs Fund adds Roche, Celgene and Exelixis drugs

Three new drugs have been added to the Cancer Drugs Fund (CDF) in a move NHS England says could benefit 900 patients per year. The Fund will add new NHS coverage in England for Roche’s Avastin (bevacizumab), Celgene’s Abraxane (albumin bound paclitaxel) and Exelixis’ Cometriq (cabozantinib). The CDF provides special funding for drugs that have [...]